Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

This study has been completed.
Information provided by:
National Institutes of Health Clinical Center (CC) Identifier:
First received: January 16, 2010
Last updated: September 29, 2011
Last verified: September 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)